316 related articles for article (PubMed ID: 29149598)
1. Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene.
Fontanals-Cirera B; Hasson D; Vardabasso C; Di Micco R; Agrawal P; Chowdhury A; Gantz M; de Pablos-Aragoneses A; Morgenstern A; Wu P; Filipescu D; Valle-Garcia D; Darvishian F; Roe JS; Davies MA; Vakoc CR; Hernando E; Bernstein E
Mol Cell; 2017 Nov; 68(4):731-744.e9. PubMed ID: 29149598
[TBL] [Abstract][Full Text] [Related]
2. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy.
Segura MF; Fontanals-Cirera B; Gaziel-Sovran A; Guijarro MV; Hanniford D; Zhang G; González-Gomez P; Morante M; Jubierre L; Zhang W; Darvishian F; Ohlmeyer M; Osman I; Zhou MM; Hernando E
Cancer Res; 2013 Oct; 73(20):6264-76. PubMed ID: 23950209
[TBL] [Abstract][Full Text] [Related]
3. Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition.
Gelato KA; Schöckel L; Klingbeil O; Rückert T; Lesche R; Toedling J; Kalfon E; Héroult M; Lejeune P; Mönning U; Fernández-Montalván AE; Bäurle S; Siegel S; Haendler B
Oncogene; 2018 Jan; 37(4):512-521. PubMed ID: 28991225
[TBL] [Abstract][Full Text] [Related]
4. BET bromodomain proteins are required for glioblastoma cell proliferation.
Pastori C; Daniel M; Penas C; Volmar CH; Johnstone AL; Brothers SP; Graham RM; Allen B; Sarkaria JN; Komotar RJ; Wahlestedt C; Ayad NG
Epigenetics; 2014 Apr; 9(4):611-20. PubMed ID: 24496381
[TBL] [Abstract][Full Text] [Related]
5. The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells.
Gallagher SJ; Mijatov B; Gunatilake D; Tiffen JC; Gowrishankar K; Jin L; Pupo GM; Cullinane C; Prinjha RK; Smithers N; McArthur GA; Rizos H; Hersey P
J Invest Dermatol; 2014 Nov; 134(11):2795-2805. PubMed ID: 24906137
[TBL] [Abstract][Full Text] [Related]
6. BET inhibitor suppresses melanoma progression
Deng G; Zeng F; Su J; Zhao S; Hu R; Zhu W; Hu S; Chen X; Yin M
Theranostics; 2020; 10(25):11428-11443. PubMed ID: 33052224
[No Abstract] [Full Text] [Related]
7. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism.
Boehm D; Calvanese V; Dar RD; Xing S; Schroeder S; Martins L; Aull K; Li PC; Planelles V; Bradner JE; Zhou MM; Siliciano RF; Weinberger L; Verdin E; Ott M
Cell Cycle; 2013 Feb; 12(3):452-62. PubMed ID: 23255218
[TBL] [Abstract][Full Text] [Related]
8. BRD4 inhibitor suppresses melanoma metastasis via the SPINK6/EGFR-EphA2 pathway.
Hu R; Li Y; Guo Y; Li X; Du S; Liao M; Hou H; Sun H; Zhao S; Su J; Chen X; Yin M
Pharmacol Res; 2023 Jan; 187():106609. PubMed ID: 36516883
[TBL] [Abstract][Full Text] [Related]
9. Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.
Sahni JM; Gayle SS; Bonk KL; Vite LC; Yori JL; Webb B; Ramos EK; Seachrist DD; Landis MD; Chang JC; Bradner JE; Keri RA
J Biol Chem; 2016 Nov; 291(45):23756-23768. PubMed ID: 27650498
[TBL] [Abstract][Full Text] [Related]
10. NF-κB signaling activation via increases in BRD2 and BRD4 confers resistance to the bromodomain inhibitor I-BET151 in U937 cells.
Hishiki K; Akiyama M; Kanegae Y; Ozaki K; Ohta M; Tsuchitani E; Kaito K; Yamada H
Leuk Res; 2018 Nov; 74():57-63. PubMed ID: 30300821
[TBL] [Abstract][Full Text] [Related]
11. In vivo selection of highly metastatic human ovarian cancer sublines reveals role for AMIGO2 in intra-peritoneal metastatic regulation.
Liu Y; Yang J; Shi Z; Tan X; Jin N; O'Brien C; Ott C; Grisoli A; Lee E; Volk K; Conroy M; Franz E; Bryant A; Campbell L; Crowley B; Grisoli S; Alexandrou AT; Li C; Harper EI; Asem M; Johnson J; Leonard A; Santanello K; Klein A; Wang Q; Zhang S; Hilliard TS; Stack MS
Cancer Lett; 2021 Apr; 503():163-173. PubMed ID: 33524500
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma.
Ambrosini G; Do C; Tycko B; Realubit RB; Karan C; Musi E; Carvajal RD; Chua V; Aplin AE; Schwartz GK
Cancer Res; 2019 May; 79(9):2415-2425. PubMed ID: 30885979
[TBL] [Abstract][Full Text] [Related]
13. The mechanisms behind the therapeutic activity of BET bromodomain inhibition.
Shi J; Vakoc CR
Mol Cell; 2014 Jun; 54(5):728-36. PubMed ID: 24905006
[TBL] [Abstract][Full Text] [Related]
14. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
[TBL] [Abstract][Full Text] [Related]
15. AMIGO2, a novel membrane anchor of PDK1, controls cell survival and angiogenesis via Akt activation.
Park H; Lee S; Shrestha P; Kim J; Park JA; Ko Y; Ban YH; Park DY; Ha SJ; Koh GY; Hong VS; Mochizuki N; Kim YM; Lee W; Kwon YG
J Cell Biol; 2015 Nov; 211(3):619-37. PubMed ID: 26553931
[TBL] [Abstract][Full Text] [Related]
16. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
Welti J; Sharp A; Yuan W; Dolling D; Nava Rodrigues D; Figueiredo I; Gil V; Neeb A; Clarke M; Seed G; Crespo M; Sumanasuriya S; Ning J; Knight E; Francis JC; Hughes A; Halsey WS; Paschalis A; Mani RS; Raj GV; Plymate SR; Carreira S; Boysen G; Chinnaiyan AM; Swain A; de Bono JS;
Clin Cancer Res; 2018 Jul; 24(13):3149-3162. PubMed ID: 29555663
[No Abstract] [Full Text] [Related]
17. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.
Coudé MM; Braun T; Berrou J; Dupont M; Bertrand S; Masse A; Raffoux E; Itzykson R; Delord M; Riveiro ME; Herait P; Baruchel A; Dombret H; Gardin C
Oncotarget; 2015 Jul; 6(19):17698-712. PubMed ID: 25989842
[TBL] [Abstract][Full Text] [Related]
18. The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors.
Wong C; Laddha SV; Tang L; Vosburgh E; Levine AJ; Normant E; Sandy P; Harris CR; Chan CS; Xu EY
Cell Death Dis; 2014 Oct; 5(10):e1450. PubMed ID: 25299775
[TBL] [Abstract][Full Text] [Related]
19. BET Proteins Exhibit Transcriptional and Functional Opposition in the Epithelial-to-Mesenchymal Transition.
Andrieu GP; Denis GV
Mol Cancer Res; 2018 Apr; 16(4):580-586. PubMed ID: 29437854
[TBL] [Abstract][Full Text] [Related]
20. BET Inhibitors Potentiate Chemotherapy and Killing of
Tan X; Tong J; Wang YJ; Fletcher R; Schoen RE; Yu J; Shen L; Zhang L
Cancer Res; 2019 Mar; 79(6):1191-1203. PubMed ID: 30674532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
